Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 2.2 Side Letter to Business Combination Agreement, Dated November 32, 2022, by and Among Larkspur Health Acquisition Corp., Larkspur Merger Sub Inc., Stephen Glover and Zyversa Therapeutics, Inc
- 3.6 Form of Certificate of Designation of Larkspur Health Acquisition Corp. Relating to the Series B Convertible Preferred Stock
- 5.1 Opinion of Alston & Bird LLP As to the Validity of the Shares of Common Stock and Warrants
- 8.1 Tax Opinion of Lowenstein Sandler LLP
- 10.19 Form of Amendment #1 to the Securities Purchase Agreement, by and Among Larkspur Health Acquisition Corp. and Each Purchaser Identified on the Signature Pages Thereto
- 23.1 Consent of Marcum LLP, Independent Registered Public Accounting Firm of Larkspur Health Acquisition Corp
- 23.2 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm of Zyversa Therapeutics, Inc
- 99.6 Consent of Cassel Salpeter & Co., LLC
- EX-FILING FEES Filing Fee Table
- Download Excel data file
- View Excel data file
Associated filings
- 15 Nov 22 EFFECT Notice of effectiveness
- 14 Nov 22 424B3 Prospectus supplement
-
3 Nov 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 20 Oct 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 27 Sep 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 12 Aug 22 S-4 Registration of securities issued in business combination transactions
ZVSA similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated April 8, 2022, with respect to the financial statements of ZyVersa Therapeutics, Inc. included in the Proxy Statement of Larkspur Health Acquisition Corp. that is made a part of the Amendment No. 3 to the Registration Statement (Form S-4 No. 333-266838) and related Prospectus of Larkspur Health Acquisition Corp. for the registration of 10,531,725 shares of its common stock.
/s/ Ernst & Young LLP
Miami, Florida
November 3, 2022